2014 Prostate Cancer Debate

Recently, a number of therapies have been approved that provide more treatment options and improve outcomes for men with metastatic castration-resistant prostate cancer (mCRPC). This expert discussion examines the latest developments in hormone therapies and asks what the future may look like for prostate cancer patients. Discussion includes: - State of the art treatment options for patients with mCRPC - The role of chemotherapy in the future management of mCRPC - Treating mCRPC patients after docetaxel therapy - Quality of life measurement - Personalised medicine in prostate cancer With: Dr Cora Sternberg, San Camillo and Forlanini Hospitals, Italy, Dr Marc Rubin, Cornell University, USA, Dr Heather Payne, University College London, UK, Dr Maria De Santis, Kaiser Franz Josef Hospital, Austria and Dr John Fitzpatrick, Irish Cancer Society and University College Dublin, Ireland This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Prof Richard Sullivan discusses a recent economic study that examines the impact and the effectiveness of cancer treatment in Europe.